Sun Pharma provides key clinical updates on oncology pipeline

Sun Pharmaceutical Industries Limited, one of India’s largest pharmaceutical companies, has shared important updates regarding its oncology pipeline, specifically focusing on Fibromun and Nidlegy™, two innovative biopharmaceutical products being developed in collaboration with its partner Philogen.

These updates, disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015, highlight both challenges and progress in clinical trials, reflecting the complex nature of cancer drug development.

Fibromun faces challenges in Phase II trials

Fibromun, being evaluated for the treatment of soft tissue sarcoma (STS) and glioblastoma, has delivered mixed clinical results in recent studies.

The Phase II FLASH study, conducted in patients with advanced soft tissue sarcoma, enrolled 94 participants who were divided into two groups:

The company continues to invest in:

Strategic outlook for Sun Pharma

These updates highlight Sun Pharma’s dual reality in drug development:

Additionally, a fourth registrational study is planned:

These studies have already been discussed with regulatory authorities, and:

The strong results from these studies have laid the groundwork for future expansion.

New registrational studies planned

Based on positive clinical outcomes, the company is preparing to launch:

These results were presented at the European Society for Medical Oncology (ESMO) 2025 conference, highlighting the drug’s potential.

Further data from both BCC and cSCC cohorts are expected to be published in 2026.

Ongoing trials and expansion plans for Nidlegy

Another study, the Phase II “Intrinsic” trial, is currently ongoing:

The Phase II “Duncan” study delivered excellent results in BCC, with:

This marks a significant step forward toward bringing Nidlegy to the U.S. market.

Strong results in non-melanoma skin cancer (NMSC)

Nidlegy has demonstrated particularly strong outcomes in non-melanoma skin cancers, including:

Importantly, a Type C meeting with the U.S. FDA was held in March 2026, where:

Nidlegy shows promising progress in skin cancer treatment

In contrast to Fibromun, Nidlegy™, a drug being developed for skin cancers, has shown encouraging results across multiple studies.

Melanoma program advances despite earlier setback

Although the company had withdrawn its earlier EMA application for melanoma in 2025, it is now preparing for a new submission in Europe during 2026.

In the United States:

Additionally, encouraging results from the FIBROSARC study in first-line soft tissue sarcoma have prompted further action.

The study showed positive survival signals, particularly in liposarcoma patients, and even reported complete remissions in some cases when Fibromun was combined with doxorubicin.

As a result:

have also struggled to significantly improve survival outcomes in glioblastoma.

However, there was a notable positive signal. The trial showed improved survival in a subgroup of patients who had limited prior exposure to alkylating agents, suggesting potential for targeted patient selection in future studies.

Ongoing and upcoming studies for Fibromun

Despite the setbacks, multiple studies are ongoing or planned, indicating a long-term strategic approach:

Unfortunately, the study did not meet its primary endpoint, which was Progression Free Survival (PFS). This outcome underscores the significant difficulty in treating pretreated soft tissue sarcoma, a condition with limited effective therapies and high unmet medical need.

Despite this setback, the company has emphasized its continued commitment to developing innovative treatments for such challenging diseases.

Glioblastoma trials show limited success but some positive signals

Fibromun was also tested in glioblastoma, one of the most aggressive and difficult-to-treat brain cancers.

In the Phase II GLIOSTAR trial, involving 163 second-line patients, the drug again failed to meet its primary endpoint. This result aligns with broader industry challenges, as several other therapies such as:

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.